Clinical Trial Update: Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of single and multiple doses of VAK694 in healthy and atopic subjects, including individuals with allergic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• VAK694

Snippet

Sponsor: Novartis | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED